KRYS News and Press, Krystal Biotech Inc. From 05/03/21

PITTSBURGH, May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global bio...

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster p...

Krystal Biotech (KRYS) announces modifications to the Statistical Analysis Plan ((SAP)) in the ongoing Phase 3 study of B-VEC for the treatment of dystrophic epidermolysis bullosa ((DEB)) based on feedback from the U.S. FDA.The trial is a randomized, double-blind, intra patient placebo-contro...

PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan (SAP) in the ongoing Phase 3 study of B-VEC for the tr...

New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosis Company expands rare genetic lung disease pipeline with KB408 for the treatment of alpha-1 antitrypsin deficiency PITTSBURGH, April 19, 2021 (G...

Krystal Biotech (KRYS), has completed enrollment in the GEM-3 study of B-VEC for dystrophic epidermolysis bullosa ((DEB)).Top-line results are expected in Q4. The trial enrolled 31 patients ranging in ages from one year to 44 years old.In each patient, a primary wound pair(s) was identif...

PITTSBURGH, March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete in the pivotal GEM-3 study of B-VEC for dystrophic epidermolysis bullosa ...

PITTSBURGH, March 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual conferences. Details for the presentations are as follows...

Krystal Biotech ([[KRYS]] -2.5%) has launched its wholly-owned subsidiary Jeune, a gene therapy firm targeting rare diseases.Bhushan Hardas a former Chief Medical Officer of Allergan's Dermatology and Medical Aesthetics business has also been appointed as the President of Jeune effective...

-  Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerability of repeat KB301 injections -  Dr. Bhushan Hardas M.D., MBA appointed President, Jeune, Inc. PITTSBURGH, March 24, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal...